 Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of 239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023. 